摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-3,4-二氟苯甲酸 | 150444-93-2

中文名称
2-氯-3,4-二氟苯甲酸
中文别名
——
英文名称
2-chloro-3,4-difluorobenzoic acid
英文别名
——
2-氯-3,4-二氟苯甲酸化学式
CAS
150444-93-2
化学式
C7H3ClF2O2
mdl
——
分子量
192.549
InChiKey
OXEOUORGNJUNFN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    277.9±35.0 °C(Predicted)
  • 密度:
    1.573±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温下应存放在干燥且密封的容器中。

SDS

SDS:75fe70ae44092544fd03078ead564ea8
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Chloro-3,4-difluorobenzoic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-3,4-difluorobenzoic acid
CAS number: 150444-93-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H3ClF2O2
Molecular weight: 192.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯-3,4-二氟苯甲酸二异丁基氢化铝1-羟基苯并三唑对甲苯磺酸盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺N,N-二异丙基乙胺 作用下, 以 四氢呋喃N,N-二甲基甲酰胺甲苯 为溶剂, 反应 31.17h, 生成 methyl 4-(2-chloro-3,4-difluorophenyl)-6-(4,5,6,7-tetrahydro-1H-indazol-5-yl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate
    参考文献:
    名称:
    [EN] DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
    [FR] DÉRIVÉS DE DIHYDROPYRIMIDINE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B
    摘要:
    本文提供了一种二氢嘧啶衍生物,可用于治疗乙型肝炎感染或由乙型肝炎引起的疾病,以及其药用或医学应用。
    公开号:
    WO2019214610A1
  • 作为产物:
    描述:
    3,4-二氟苯甲酸四甲基乙二胺仲丁基锂六氯乙烷 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 3.0h, 以45%的产率得到2-氯-3,4-二氟苯甲酸
    参考文献:
    名称:
    [EN] DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
    [FR] DÉRIVÉS DE DIHYDROPYRIMIDINE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B
    摘要:
    本文提供了一种二氢嘧啶衍生物,可用于治疗乙型肝炎感染或由乙型肝炎引起的疾病,以及其药用或医学应用。
    公开号:
    WO2019214610A1
点击查看最新优质反应信息

文献信息

  • AMINO ACID COMPOUNDS AND METHODS OF USE
    申请人:Pliant Therapeutics, Inc.
    公开号:US20200109141A1
    公开(公告)日:2020-04-09
    The invention relates to compounds of formula (I): or a salt thereof, wherein R 1 , G, L 1 , L 2 , L 3 , and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ 1 integrin and αvβ 6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    本发明涉及如下公式(I)的化合物: 或其盐,其中R1、G、L1、L2、L3和Y如本文所述。公式(I)的化合物及其药物组合物是αvβ1整合素和/或αvβ6整合素的一种或两种的抑制剂,用于治疗纤维化,如非酒精性脂肪肝炎(NASH)、特发性肺纤维化(IPF)和非特异性间质性肺炎(NSIP)。
  • Novel Receptor Antagonists and Their Methods of Use
    申请人:Chambers J. Laura
    公开号:US20080009541A1
    公开(公告)日:2008-01-10
    The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    本发明涉及一种新型的氧代脯氨酰胺衍生物,其化学式为(I),可以调节P2X7受体功能,并能够拮抗P2X7受体上ATP的作用,以及利用这些化合物或其药物组合物治疗由P2X7受体介导的疾病,例如疼痛、炎症和神经退行性疾病。
  • [EN] HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS<br/>[FR] DÉRIVÉS HÉTÉROARYLDIHYDROPYRIMIDINE ET MÉTHODES DE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2019001420A1
    公开(公告)日:2019-01-03
    Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    本文提供了一些用于治疗HBV感染的化合物,以及其药物组合物和抑制、抑制或预防受试者HBV感染的方法。
  • [EN] 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS<br/>[FR] DÉRIVÉS DE 4-BENZOYL-1-SUBSTITUÉ-PIPÉRAZIN-2-ONE COMME MODULATEURS DE P2X7
    申请人:GLAXO GROUP LTD
    公开号:WO2009053459A1
    公开(公告)日:2009-04-30
    The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: A is C1-6alkyl, C3-6cycloalkyl, -CH2-R6, -CHMe-R7, -CMe2-R7, or optionally substituted aryl; wherein, when A is optionally substituted aryl, said aryl group is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of halogen, C1-6alkyl, -CF3, C1-4alkoxy, C1fluoroalkoxy, cyano, NR8R9; and pyridyl wherein the pyridyl is optionally substituted by one methyl; R1 is chlorine, fluorine, -CF3, cyano or C1-6alkyl; R2, R3 and R5 independently are hydrogen, fluorine, chlorine, -CF3, cyano or C1-6alkyl, such that at least one of R2, R3 and R5 is other than hydrogen; R4 is hydrogen. These compounds and salts are thought to be P2X7 receptor antagonists. The invention also provides the use of the compound or salt for the manufacture of a medicament for the treatment of pain, inflammation, rheumatoid arthritis, osteoarthritis, or a neurodegenerative disease.
    该发明提供了一个具有以下式(I)的化合物或其药用盐,其中:A为C1-6烷基,C3-6环烷基,-CH2-R6,-CHMe-R7,-CMe2-R7或可选择地取代的芳基;其中,当A为可选择地取代的芳基时,所述芳基可选择地取代为1至3个取代基,这些取代基可以相同或不同,选自卤素,C1-6烷基,-CF3,C1-4烷氧基,C1氟烷氧基,氰基,NR8R9;和吡啶基,其中吡啶基可选择地被一个甲基取代;R1为氯,氟,-CF3,氰基或C1-6烷基;R2、R3和R5独立地为氢,氟,氯,-CF3,氰基或C1-6烷基,使得R2、R3和R5中至少有一个不是氢;R4为氢。这些化合物和盐被认为是P2X7受体拮抗剂。该发明还提供了该化合物或盐用于制备用于治疗疼痛、炎症、类风湿关节炎、骨关节炎或神经退行性疾病的药物的用途。
  • Synthesis of benzotriazoles derivatives and their dual potential as α-amylase and α-glucosidase inhibitors in vitro: Structure-activity relationship, molecular docking, and kinetic studies
    作者:Shehryar Hameed、Kanwal、Faiza Seraj、Rafaila Rafique、Sridevi Chigurupati、Abdul Wadood、Ashfaq Ur Rehman、Vijayan Venugopal、Uzma Salar、Muhammad Taha、Khalid Mohammed Khan
    DOI:10.1016/j.ejmech.2019.111677
    日期:2019.12
    Benzotriazoles (4-6) were synthesized which were further reacted with different substituted benzoic acids and phenacyl bromides to synthesize benzotriazole derivatives (7-40). The synthetic compounds (7-40) were characterized via different spectroscopic techniques including EI-MS, HREI-MS, 1H-, and 13C NMR. These molecules were examined for their anti-hyperglycemic potential hence were evaluated for
    合成了苯并三唑(4-6),其进一步与不同的取代的苯甲酸和苯甲酰溴反应以合成苯并三唑衍生物(7-40)。合成化合物(7-40)通过不同的光谱技术进行了表征,包括EI-MS,HREI-MS,1H-和13C NMR。检查这些分子的抗降血糖潜力,因此评估其α-葡萄糖苷酶和α-淀粉酶抑制活性。所有苯并三唑均在2.00-5.6和2.04-5.72μM的IC50值范围内分别显示出对α-葡萄糖苷酶和α-淀粉酶的中等至良好的抑制活性。为了理解结构-活性关系,将合成化合物分为“ A”和“ B”两类。化合物25(IC50 = 2.41±1.31μM),(IC50 = 2.5±1.21μM),发现36(IC50 = 2.12±1.35μM)(IC50 = 2.21±1.08μM)和37(IC50 = 2.00±1.22μM)(IC50 = 2.04±1.4μM)在芳环上有氯取代/ s对α-葡萄糖苷酶和α-淀粉酶最
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐